NORCROSS, Ga. , March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination
NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein . The letter reads as follows: Dear
Richard E. Uihlein, Board Chair, expresses interest in investing $20.0 million in the Rights Offering NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration
Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
NORCROSS, Ga. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at Berenberg NASH Day at the Berenberg Offices
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years NORCROSS, Ga. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its
NORCROSS, Ga. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of credit entered into on December 19, 2017 , has been extended by one year for both
NORCROSS, Ga. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at the 2nd Annual Anti-Fibrotic Drug
NORCROSS, Ga. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today reported financial results for its third fiscal quarter, which ended September 30, 2018 , and provided a business update.
NORCROSS, Ga. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in Galectin Therapeutics’ NASH-CX Phase 2 Clinical Trial has been accepted for
